Anti-iNOS (NOSII) Antibody, clone 2G17 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.

Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.

Learn more about ZooMAb here.

Clone 2G17 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects iNOS (NOS II). It targets an epitope within the first 130 amino acids from the N-terminal region.

GST/His-tagged recombinant fragment corresponding to the first 130 amino acids from murine Inducible nitric oxide synthase (iNOS).

Anti-iNOS (NOSII), clone 2G17 ZooMAb, Cat. No. ZRB1449, is a recombinant Rabbit monoclonal antibody that specifically targets iNOS (NOSII) and is tested for use in Affinity Binding Assay, Immunocytochemistry, Immunohistochemistry, and Western Blotting.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected iNOS (NOSII) in RAW 264.7 cells treated with Lipopolysaccharide.

Immunohistochemistry Analysis: A 1:1,000 dilution from a representative lot detected iNOS (NOSII) in mouse colon tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound recombinant murine iNOS (NOSII) protein fragment with a KD of 1.68 x 10-9 in an affinity binding assay.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Nitric oxide synthase, inducible (UniProt: P29477; also known as EC:1.14.13.39, Inducible NO synthase, Inducible NOS, iNOS, Macrophage NOS, MAC-NOS, NOS type II, Peptidyl-cysteine S-nitrosylase NOS₂) is encoded by the Nos₂ (also known as Inosl) gene (Gene ID: 18126) in murine species. Nitric oxide synthases (nNOS, iNOS, eNOS) are single polypeptides that differ in their rates of Nitric oxide (•NO) synthesis, Ca²⁺- dependence, cytochrome c reduction, and NADPH utilization. For their catalytic activities NOS isoforms require three distinct domains: (a) a reductase domain, (b) a calmodulin-binding domain, and (c) an oxygenase domain. The reductase domain contains the FAD and FMN moieties. The oxygenase domain, which contains the binding sites for heme, tetrahydrobiopterin, and arginine, catalyzes the conversion of L-arginine to citrulline and •NO. The maximal rate of •NO synthesis is established by the intrinsic maximum ability of the reductase domain to deliver electrons to the heme domain. The iNOS is expressed in a variety of cells and is localized mainly in the cytoplasm. It binds tightly to calmodulin at very low Ca²⁺ levels, hence the enzyme activity is unaffected by changes in intracellular Ca²⁺ levels. The complete Ca²⁺-independence of inducible NOS requires interactions of calmodulin with both the calmodulin-binding motif and the flavoprotein domain. This property is important in assuring a long-lasting release of •NO. The iNOS is capable of producing large amounts of •NO when induced by mediators such as TNF-α, IL-1, IL-2, IL-6, and γ-IFN. The amount of •NO released by iNOS falls in the nanomolar range. The iNOS-induced release of •NO plays an important role in the macrophage-mediated response to infections, where •NO acts as an effector molecule to kill the invading organism. This toxic effect is achieved via the production of highly reactive nitrogen and oxygen intermediates. The induction of iNOS has been implicated in increased blood flow to the tumor site resulting in tumor growth. The cytotoxic effects of •NO have also been reported against cancer cells. Over-expression of iNOS has been implicated in a number of pathologies including septic shock where excessive generation of •NO, in response to infection, leads to a serious drop in blood pressure and subsequent dysfunction of multiple organs. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

0.3 mg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.